[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575473":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":46,"collaborators":11,"id":50,"slug":11,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Hyogo Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional treatments with middle meningeal artery embolization","EXPERIMENTAL",null,[13],"Procedure: Middle meningeal artery embolization",{"label":15,"type":16,"description":11,"interventionNames":11},"Conventional treatments alone","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"PROCEDURE","Middle meningeal artery embolization","Middle meningeal artery embolization within 7 days after randomization",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Kazutaka Uchida, MD, PhD","CONTACT","81+798-45-6458","fu-sakakibara@hyo-med.ac.jp",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Nishinomiya","Hyōgo","663-8501","Japan","JP",{"type":38,"coordinates":39},"Point",[40,41],135.33199,34.71562,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":45,"phoneExt":11,"email":28},"+81-798-45-6458",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Kazutaka Uchida","Associate Professor (Stroke Center)","100575473",false,"NCT06772740","Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma","Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma (COMPLEMENT Study)","Inclusion Criteria:\n\n1. Age \\>=18\n2. pre-mRS 0-3\n3. Hematoma thickness \\>=10mm\n4. Having at least one risk factor Risk factor: Age \\>=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score \\>3, Preoperative volume \\>=130ml, Preoperative midline shift \\>=8mm, CT appearance (Homogeneous, laminar or separated)\n\nExclusion Criteria:\n\n1. Cr \\>=1.8\n2. Plt \\\u003C50,000, PT-INR \\>2\n3. Life expectancy \\\u003C6 months","ALL","18 Years",{"count":59,"type":60},600,"ESTIMATED","INTERVENTIONAL",[63],"NA","COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.",[66,67],"Endovascular Treatment","Chronic Subdural Hematoma","2025-05-26",{"date":70,"type":71},"2025-05-28","ACTUAL",{"date":73,"type":71},"2024-12-23",{"date":75,"type":60},"2029-03-31",{"name":48,"class":6},1]